These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 36920318)

  • 1. MC3/SAINT-O-Somes, a novel liposomal delivery system for efficient and safe delivery of siRNA into endothelial cells.
    He Y; Barlag M; Plantinga JA; Molema G; Kamps JAAM
    J Liposome Res; 2023 Dec; 33(4):328-337. PubMed ID: 36920318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-VCAM-1 SAINT-O-Somes enable endothelial-specific delivery of siRNA and downregulation of inflammatory genes in activated endothelium in vivo.
    Kowalski PS; Zwiers PJ; Morselt HW; Kuldo JM; Leus NG; Ruiters MH; Molema G; Kamps JA
    J Control Release; 2014 Feb; 176():64-75. PubMed ID: 24389338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-VCAM-1 and anti-E-selectin SAINT-O-Somes for selective delivery of siRNA into inflammation-activated primary endothelial cells.
    Kowalski PS; Lintermans LL; Morselt HW; Leus NG; Ruiters MH; Molema G; Kamps JA
    Mol Pharm; 2013 Aug; 10(8):3033-44. PubMed ID: 23819446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a Combined Lipid-Based Nanoparticle Formulation for Enhanced siRNA Delivery to Vascular Endothelial Cells.
    He Y; Bi D; Plantinga JA; Molema G; Bussmann J; Kamps JAAM
    Pharmaceutics; 2022 Sep; 14(10):. PubMed ID: 36297521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted SAINT-O-Somes for improved intracellular delivery of siRNA and cytotoxic drugs into endothelial cells.
    Adrian JE; Morselt HW; Süss R; Barnert S; Kok JW; Asgeirsdóttir SA; Ruiters MH; Molema G; Kamps JA
    J Control Release; 2010 Jun; 144(3):341-9. PubMed ID: 20226822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effective siRNA delivery to inflamed primary vascular endothelial cells by anti-E-selectin and anti-VCAM-1 PEGylated SAINT-based lipoplexes.
    Leus NG; Talman EG; Ramana P; Kowalski PS; Woudenberg-Vrenken TE; Ruiters MH; Molema G; Kamps JA
    Int J Pharm; 2014 Jan; 459(1-2):40-50. PubMed ID: 24239833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. VCAM-1 specific PEGylated SAINT-based lipoplexes deliver siRNA to activated endothelium in vivo but do not attenuate target gene expression.
    Leus NG; Morselt HW; Zwiers PJ; Kowalski PS; Ruiters MH; Molema G; Kamps JA
    Int J Pharm; 2014 Jul; 469(1):121-31. PubMed ID: 24746643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endothelium-targeted delivery of dexamethasone by anti-VCAM-1 SAINT-O-Somes in mouse endotoxemia.
    Li R; Kowalski PS; Morselt HWM; Schepel I; Jongman RM; Aslan A; Ruiters MHJ; Zijlstra JG; Molema G; van Meurs M; Kamps JAAM
    PLoS One; 2018; 13(5):e0196976. PubMed ID: 29763440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SAINT-liposome-polycation particles, a new carrier for improved delivery of siRNAs to inflamed endothelial cells.
    Kowalski PS; Kuninty PR; Bijlsma KT; Stuart MC; Leus NG; Ruiters MH; Molema G; Kamps JA
    Eur J Pharm Biopharm; 2015 Jan; 89():40-7. PubMed ID: 25460585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted transfection increases siRNA uptake and gene silencing of primary endothelial cells in vitro--a quantitative study.
    Asgeirsdóttir SA; Talman EG; de Graaf IA; Kamps JA; Satchell SC; Mathieson PW; Ruiters MH; Molema G
    J Control Release; 2010 Jan; 141(2):241-51. PubMed ID: 19766679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting Rapamycin to Podocytes Using a Vascular Cell Adhesion Molecule-1 (VCAM-1)-Harnessed SAINT-Based Lipid Carrier System.
    Visweswaran GR; Gholizadeh S; Ruiters MH; Molema G; Kok RJ; Kamps JA
    PLoS One; 2015; 10(9):e0138870. PubMed ID: 26407295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced siRNA delivery using cationic liposomes with new polyarginine-conjugated PEG-lipid.
    Kim HK; Davaa E; Myung CS; Park JS
    Int J Pharm; 2010 Jun; 392(1-2):141-7. PubMed ID: 20347025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preparation of a Cyclic RGD: Modified Liposomal SiRNA Formulation for Use in Active Targeting to Tumor and Tumor Endothelial Cells.
    Sakurai Y; Hada T; Harashima H
    Methods Mol Biol; 2016; 1364():63-9. PubMed ID: 26472442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of DLin-MC3-DMA and ALC-0315 for siRNA Delivery to Hepatocytes and Hepatic Stellate Cells.
    Ferraresso F; Strilchuk AW; Juang LJ; Poole LG; Luyendyk JP; Kastrup CJ
    Mol Pharm; 2022 Jul; 19(7):2175-2182. PubMed ID: 35642083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endothelial cell-targeting, ROS-ultrasensitive drug/siRNA co-delivery nanocomplexes mitigate early-stage neutrophil recruitment for the anti-inflammatory treatment of myocardial ischemia reperfusion injury.
    Hou M; Wu X; Zhao Z; Deng Q; Chen Y; Yin L
    Acta Biomater; 2022 Apr; 143():344-355. PubMed ID: 35189380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cell mimetic liposomal nanocarriers for tailored delivery of vascular therapeutics.
    Mattern-Schain SI; Fisher RK; West PC; Grimsley LB; Harris TM; Grandas OH; Best MD; Mountain DJH
    Chem Phys Lipids; 2019 Jan; 218():149-157. PubMed ID: 30582896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. VCAM-1-binding peptide targeted cationic liposomes containing NLRP3 siRNA to modulate LDL transcytosis as a novel therapy for experimental atherosclerosis.
    Jia X; Bai X; Yang X; Wang L; Lu Y; Zhu L; Zhao Y; Cheng W; Shu M; Mei Q; Jin S
    Metabolism; 2022 Oct; 135():155274. PubMed ID: 35917895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and Characterization of a New Cationic Lipid: Efficient siRNA Delivery and Anticancer Activity of Survivin-siRNA Lipoplexes for the Treatment of Lung and Breast Cancers.
    Vaidya S; Mohod A; Eedara AC; Andugulapati SB; Pabbaraja S
    ChemMedChem; 2023 Aug; 18(16):e202300097. PubMed ID: 37306531
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Algarni A; Pilkington EH; Suys EJA; Al-Wassiti H; Pouton CW; Truong NP
    Biomater Sci; 2022 May; 10(11):2940-2952. PubMed ID: 35475455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Silencing of Tumor Necrosis Factor Receptor-1 in Human Lung Microvascular Endothelial Cells Using Particle Platforms for siRNA Delivery.
    Bai L; Andersson HA; McConnell KI; Chan DL; Hernandez M; Gonzalez J; Liu X; La Francesca S; Sakamoto JH; Serda RE
    Curr Drug Targets; 2015; 16(13):1531-9. PubMed ID: 26201489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.